After achieving operating profit in 2024 (excluding stock-based compensation), BioCryst anticipates nearing quarterly profitability and positive cash flow ... include a new drug application ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025- -New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet ...

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by ...

Though not a new methodology ... chart review studies can generate the evidence to support increasingly complex value demonstration, reimbursement and market launch decision-making. "Drug ...

Report Ocean has recently released its “Saudi Arabia Lateral Flow Assays Market” Research Report for the years 2024-2032, presenting a comprehensive analysis of the market. This report extensively ...

Discover the top stocks for the new year selected by Needham analysts, including ACV Auctions, Alcon, Alegro Microsystems, ...

This article uses today’s market data to explore the next cryptocurrency to explode. Below are details of what makes these ...

Trudeau out, Trump in, tariffs up, trade down – as Canadians embark on 2025, it’s clear this will be a year of upheaval ...

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary ...

We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...